PHP74 Cost-of-Illness of Patient-Reported Adverse Drug Events – a Population-Based Survey  by Gyllensten, H. et al.
latory, 10,000 more psychiatric and 3,000 more traumatological cases). Are the
cost-savings in balance with the outcome?
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OBJECTIVES: The potential for comparative effectiveness research (CER) to char-
acterize the benefits of new, expensive pediatric therapies has expanded greatly
due to recent advances in the measurement of patient-reported outcomes(PROs)
and the rise of biomedical informatics. To enhance CER and better inform alloca-
tions of scarce health care resources, this study examines 1) how much are adults
willing to trade child health-related quality of life (HR-QoL) for reduced child mor-
tality, and 2) which HR-QoL outcomes in childhood are more preferred?METHODS:
In this discrete choice experiment (DCE), 2,000 adults from a national panel com-
plete a series of 40 paired comparisons, either choosing between child HR-QoL
outcomes and longevity or choosing between alternative child HR-QoL outcomes.
Under this pivoted partial profile design, each health problem occurs at either age
7 or 11, will last for either 6 or 12 months, and be described using adjectival state-
ments derived from the EQ-5D-Y, Behavioral Problems Index (BPI), and the National
Survey of Children with Special Health Care Needs (NS-CSHCN). RESULTS: The
study is currently being fielded.The results will address the 2 primary aims as well
as produce quality-adjusted life year (QALY) estimates for child health outcomes.
Applications of these estimates will be exemplified using the NS-CSHCN and other
available pediatric health databases. CONCLUSIONS: While much of the literature
of health valuation has focused on adult outcomes, this is the first national valua-
tion study of child HR-QoL outcomes. Future work may examine the value of a
QALY by age.
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OBJECTIVES: The concept of hospital-at-home means that home treatment is pro-
vided to patients who would otherwise have been treated in the hospital. Hospital
admissions may be shortened (early assisted discharge, EAD) or avoided. This may
lead to lower costs, but there is a risk that savings are overestimated if homecare
and other relevant outpatient costs are not taken into account appropriately or if
average or generic prices per inpatient day are applied. The objective of this study
was to assess the quality of cost analyses of hospital-at-home studies for acute
conditions published from 1996 through 2011 and to present an overview of evi-
dence on cost savings. METHODS: The Medline and NHS HEED databases were
searched. Methodological quality was assessed using the Quality of Health Eco-
nomic Studies instrument (QHES). Cost calculations were considered incorrect if
they failed to meet four criteria. Unit costs of inpatient hospital days had to be
disease-specific. The decreasing intensity of care over the course of an admission
had to be reflected in costs of inpatient days. In studies from the societal perspec-
tive, informal care costs had to be included. Violating any of these criteria leads to
overestimation of savings from hospital-at-home. Finally, follow-up had to be at
least one month in order to capture relevant downstream costs, in particular for
readmissions. RESULTS: The average QHES score was 65 (out of 100) . Only 5 out of
29 studies met all criteria and had a sufficiently clear explanation of their method-
ology. The most frequent problem was the use of average costs per inpatient hos-
pital day, which was problematic in at least 11 EAD studies. Follow-up was too
short in 13 studies. Informal care costs lacked in one study that stated to adopt a
societal perspective. CONCLUSIONS: While most studies found cost savings, these
were probably overestimated.
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COST EFFECTIVENESS ANALYSIS OF FACILITY AND COMMUNITY BASED
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OBJECTIVES: In Uganda, the number of new acceptors of family planning (FP) ser-
vices is still low, partly due to limited use of cost effective delivery approaches.
Currently, FP is delivered through community based distribution (CBD) and facility
based distribution (FBD). However, FBD remains the preferred approach despite the
effectiveness and low cost nature of CBDs. The objective of this study was to com-
pare the cost effectiveness of facility and community based provision of FP by a
non-government organization. METHODS: Cost effectiveness study was done us-
ing a providers’ perspective in an urban setting of Kampala. Cost data was collected
by reviewing available accounting records and effectiveness in couple years of
protection (CYP) was determined using client cards for the period January 2008 to
December 2010. Both approaches were analyzed using Tree-Age Pro 2011, with the
facility based approach as the comparator. Cost effectiveness was determined us-
ing a decision model based on the WHO recommended FP delivery procedures. Net
Health Benefit analysis was performed and results were subjected to sensitivity
analysis. RESULTS: CBDs had a lower cost effectiveness ratio of US $ 21.21 per CYP
compared to US $ 37.17 per CYP for the FBD approach. Counseling rates were higher
for CBDs with 95%, compared to 69% for FBDs. CBDs yielded‘ cost savings of US $
39.43 for every CYP gained compared to FBDs. CONCLUSIONS: The CBD approach
was more cost effective than FBDs in increasing FP use. Increasing community
based provision of low cost FP methods and implants is an effective way of increas-
ing FP use in poor urban settings.
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OBJECTIVES: The Turkish population health status improved significantly with the
implementation of the Health Transformation Programme (HTP) and reference
pricing system in 2004.This study analyzed pharmaceutical industry dynamics due
to these changes in Turkey since 2004. METHODS: Using data from the Turkish
Statistical Institute Industry Database (2001-2011), trends in total, production and
pharmaceutical industry production indexes were evaluated. Interrupted time se-
ries models were used to determine the effect of changes in 2004. Using the IMS
LifeLink Health Plan Claims Dataset (2004-2011), pharmaceutical market growth
rate trends were analyzed. Subgroup analysis was performed for brand, generic,
and 20-year old drugs. Both domestic and imported drug shares (units, expendi-
tures) were compared (2005-2011). RESULTS: The 2004 reference pricing system
implementation negatively affected the pharmaceutical production index, with
discounts ranging from 1% to 80% for approximately 1,000 medications based on
comparisons of biologically-equivalent products and pharmaceutical prices in five,
low-price European countries (p0.01). There were no significant changes in total
and production industry indexes. Although brand medication market shares re-
mained constant across the years (2004: 42.2%, 2011: 42.6%), unit shares signifi-
cantly increased, (2004: 12.4%, 2011: 16.9%). The opposite trend occurred in the
generic market. Although generic medication expenditures slightly increased
(2004: 14.6%, 2011: 16.2%), unit consumption decreased (2004: 13.6%, 2011: 9.7%).
The 2004-2011 trends for unit and cost shares were not significantly different for
20-year old drugs (cost share: 43.3% vs. 41.2%, unit consumption: 74.0% vs. 73.4%,
respectively). CONCLUSIONS: Changing the pricing systems with instantaneous
amendments of the regulations impacts not only the reduction of drug prices and
fiscal policy but also the structure and investments of the pharmaceutical industry.
While solutions are being developed to increase drug expenses, long-term perspec-
tive of the industry’s situation and monitoring of effects are important with respect
to sustainability.
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OBJECTIVES:The development and research in health care industry has constantly
created new medical materials which provide more functional and lower side-
effects than former medical materials, but the price become more expensive rela-
tively. In order to balance the trade-off between medical quality and cost reduction,
hospitals have to keep making critical decisions on choosing a best cost-effective-
ness of hospital materials. This study aims to develop approaches for the evalua-
tion of hospital materials. METHODS: Since it is a multi-criteria decision-making
problem, we first screen the critical factors and dichotomize them into two cate-
gories, the quantitative indicators and the qualitative indicators. The quantitative
indicators include “daily expenses”, “profits”, “consumption of quantity” and “de-
fective rate”. The qualitative indicators include “manufacture capability”, “physi-
cian preference”, “special function or design” and “safety and convenience”. We
proposed to evaluate the quantitative indicators and the qualitative indicators by
data envelopment analysis and analytic hierarchy process, respectively. RESULTS:
This study uses four items of wound dressing for effectiveness evaluation (the code
A, B, C, D to replace there’s brand names). First we accord to operation definition
from the quantitative indicators to collect relevant data, and we analysis those
data. Item A in the DEA method analysis results is the most effective, item D is the
second, and item C is the worst. The consultants compare four items in pairs from
the qualitative indicators, calculating the weighted by the relative importance of
four items. Analysis on the four qualitative indicators, item D in the AHP method
analysis results is the most effective, item A is the second, and item C is the worst.
CONCLUSIONS: The proposed approaches are able to acquire a ranking of the
effectiveness of hospital materials. Following our case study, we conclude that the
proposed approaches may serve as more objective and effective decision-support
tools for the decision makers.
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OBJECTIVES: To estimate the cost of illness (COI) of self-reported adverse drug
events (ADE) and the COI resulting from self-reported adverse drug reactions (ADR)
and sub-therapeutic effects of medication therapy (STE), from the health care per-
spective in a population-based study. METHODS: In 2010, a random sample of
14,000 Swedish residents, aged 18 years and older, received a cross sectional postal
survey, including questions about experienced ADEs (ADRs, STEs, untreated indi-
cations, drug dependence, and drug intoxications), overall health care use and
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health care use resulting from ADRs and STEs. The prevalence-based cost-of-ill-
ness analysis included direct costs for drugs, from the Swedish Prescribed Drug
Register, and health care use, based on national statistics, during a 30 day
study-period. RESULTS: Of the 7099 respondents, 1,377 reported at least one ADE
and 943 reported an ADR or STE. During the study-period, respondents with/with-
out self-reported ADEs respectively reported 124/164 general practitioner visits,
182/310 nurse visits, 191/310 specialist physician or emergency department visits,
39/48 home-health care visits, 159/283 other somatic visits, 4/4 psychiatrist visits,
120/72 other psychiatric visits, 20/17 hospitalizations, 267/228 health care contacts
by phone or mail, and the use of 3,908/8,663 prescription medicines. The average
direct cost per respondent was higher among respondents reporting ADEs com-
pared to those not reporting an ADE (mean SD): EUR 202.0 901.2 vs. EUR 61.2
356.9 (p0.001). The average direct costs of respondents reporting at least one ADR
or STE were EUR 239.6 950.7, and costs resulting from ADRs or STEs were EUR 16.8
 150.5 and EUR 33.4  266.9, respectively. CONCLUSIONS: According to our re-
sults, the resource use and costs associated with ADEs are extensive, and occurs
both in hospitals and primary care. There is a need to further examine the rela-
tionships between self-reported ADEs and the high overall COI, and study the
indirect costs of self-reported ADEs.
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OBJECTIVES: Policy makers pay more and more attention to the orphan drug mar-
ket. Pharmaceutical companies are suspected to take advantage of the legislation.
Moreover, granted an orphan designation (OD) could be associated with higher
prices. The aim of this work is to assess the impact of the current European orphan
drug legislation on prices within the rare disease market of the largest University
Medical Center in France (AP-HP). METHODS: We included all drugs with exclu-
sively rare disease indications, with or without (control group) European OD prior
to European marketing authorization. We collected 2011 AP-HP prices and addi-
tional characteristics: prevalence of rare diseases; alternative drug existence and
improvement in medical benefit (ASMR) assessed by the French National Authority
for Health (HAS). RESULTS: From drugs indicated for rare diseases available in
AP-HP, we retrieved those for which all additional characteristics were document-
ed: 41 drugs with OD, 17 without OD. The contribution to the growth of the overall
drug expenditures in AP-HP reached 1.16 points out of 3.40 points for OD drugs (99%
of growth was explained by 3 drugs) and 0.39 for non OD drugs. No statistically
significant difference in the price distribution was found between OD drugs (me-
dian: €180.4; interquartile range: €679.9) and non OD drugs (median: €443.9; inter-
quartile range: €1433.1) (p0.19). The price distributions were scattered (standard
deviation: 1040.2 and 3512.1 respectively). Other characteristics between the two
groups were not statistically different. CONCLUSIONS: Concerns on the growing
budgetary pressure of orphan drugs may affect social solidarity, and yet this study
underlines the heterogeneity of the rare disease market. From these study results,
OD approval should not be considered as the only price inflation cause. If the
legislation should be adapted to limit windfall effects for pharmaceutical compa-
nies, the support of innovation in a fairness and egalitarian way is needed.
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In Brazil, the mandatory coverage of medical assistance by HMOs are reviewed
every two years by the regulatory agency of the government. The incorporation of
new technologies brings as a consequence the concern about rising costs. Most
HMOs in Brazil does not have sufficient structure for conducting studies to evaluate
adequately the impact on its budget.OBJECTIVES: Evaluate the economic impact of
expansion of coverage through an economic health model that allows to simulate
the results of any HMOs. METHODS: We developed a decision support tool that
automates the analysis of economic impact of new coverage according to the pro-
file of the HMOs. The default rates used were based on the annual incidence of
diseases and their prevalence according to sex, age, and history of use of proce-
dures in the population. The costs of events considered the tariffs applied by HMOs
and benchmarked prices commonly used. Adjustment coefficients were developed
based on indicators of the real world in order to better reflect the market. As a basic
principle, we followed the guidelines of the International Society of Pharmacoeco-
nomics and Outcomes Research - ISPOR regarding the best practices.RESULTS:The
total addition in the medical and hospital expenses resulting from the incorpora-
tion of technology was of $ 2.02 per capita per month (plus 1.97%). The relative
impact of major procedures was of $ 1.02 for immunobiological therapy (0.99%), $
0.70 for eye treatment with antiangiogenic chemotherapy (0.68%) and $ 0.30 for the
other corporate events (0.29%).CONCLUSIONS:The use of tools based on economic
models enables to simulate variations in utilization rates, access to the use of
procedures and costs, reducing the uncertainty of some health indicators. This
makes it possible to predict scenarios that better represent the incorporation of
technologies in the Brazilian private HMOs’ market.
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OBJECTIVES: To compare health expenditure as total % of GDP, per capita PPP and
in US dollars as well as total drug expenditure with top ten ATC groups with highest
expenditure in 2009 and 2010 in Bosnia & Herzegovina (B&H) and Croatia (CRO).
METHODS: Research was based on data published in latest official annual reports
from two national Drug Agencies and official reports from The World Bank. Top ten
ATC groups were identified and compared for the period of two years – 2009 and
2010. RESULTS:The Health expenditure in 2009 as total (% of GDP) in B&H was 10.94
and in CRO it was 7.83. Total drug expenditure in B&H was 238.8 mil EUR compared
to 269 in 2010 (increase of 11,23%), while in CRO it was 625.6 mil EUR compared to
664.5 in 2010 (increase of 5,85%). Top 10 ATC 1st level drug groups with highest
expenditure in both countries in 2009 and 2010 were rather similar but on ATC 2nd
level we observed significant differences in the share of relevant ATC groups with
leading C09, J01 and L01 for 2009 and C09, J01 and A10 for 2010 in B&H. Leading
groups in CRO for 2009 were L01, J01 and C09, and for 2010 J01, C09 and L01. No
drugs from C10 group were present in top ten ATC 2nd level in B&H.
CONCLUSIONS: CRO has universal health care system with twice smaller increase
in total drug expenditure compared to B&H. B&H needs unique essential drug list as
it is a country with decentralized health care system including drug politics and
positive reimbursement drug lists.
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OBJECTIVES: Different payment schemes have been implemented in Europe to
stimulate integrated chronic care and to reduce health care expenditure. We aimed
to investigate the impact of different payment schemes on national total health
care expenditures. METHODS: We first identified European countries with pay-
ment reforms directed at integrated chronic care. Further, we conducted 14 inter-
views with chronic care experts in England, the Netherlands, Germany, Denmark,
Austria, and France to get detailed information about the reforms and the facilita-
tors and barriers for implementation. Last, we used a difference-in-differences
(DID) model to estimate differences in health care expenditure trends before and
after the introduction of a payment scheme between intervention countries and
control countries. Intervention countries included countries with a pay-for-coor-
dination (P4C), pay-for-performance (P4P), and/or bundled payment for integrated
chronic care. We used OECD and WHO data from 1996 to 2010. RESULTS: The
interviews showed that P4C in Austria, Denmark and France failed to control grow-
ing health care expenditure. This was attributed mainly to misaligned incentives
between public insurers and local authorities. In contrast, P4P in France and Eng-
land appeared to have a positive impact on reducing costs. The large financial
incentives for care providers and explicit activity-based guidelines were the most
important success factors. Bundled payments in the Netherlands and Germany
increased transparency and promoted quality of care but at higher costs. These
findings are in line with the quantitative results where the health care expenditure
per capita decreased by 70 euro (p0.002) after the implementation of P4P and
increased by 75 euro (p0.040) after the implementation of bundled payments. The
P4C had an insignificant effect. CONCLUSIONS: Payment schemes are potentially
powerful tools to stimulate the delivery of integrated care and influence health care
expenditure. P4P appears to be the most appealing in reducing health care expen-
diture.
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OBJECTIVES: Pharmaceutical market was put in the centre of the Stand-By Ar-
rangement (SDR) agreement. The main target was to control pharmaceutical ex-
penditure and to implement new policies in the pharmaceutical sector. Given these
reforms the aim of the study was to evaluate stakeholder’s views regarding these
measures and the future of the pharmaceutical market in Greece. METHODS: A
qualitative study, using the method of semi-structured interviews was conducted
using an open-ended questions guide. In total 17 interviews (out of 24 targeted
stakeholders) were conducted, tape recorded, transcribed and content analyzed.
The participants represented public and private sector organizations and academic
organizations as well that are involved in the pharmaceutical market and policy.
RESULTS: Rising pharmaceutical expenditure, chronic distortions of the pharma-
ceutical market such as increasing number of health professionals and lack of strict
regulations were mentioned as the main characteristics of the pharmaceutical
market in Greece. These problems along with the financial crisis in Greece created
a pessimistic environment for the pharmaceutical market and magnified the ex-
isting problems because of the hasty and non-organized decisions that were taken
under the pressure of economic crisis. Stakeholders estimated that the next 4-5
years will be hard for the industry and the recession in this sector cannot be
avoided. However, they predict that after this period everything will come back to
normal. CONCLUSIONS: Stakeholders representing the public sector had more
positive views compared to those coming from the private sector or academic
institutions that expressed negative opinions or were in generally more skeptical.
The greatest concern however on all groups was that the continuous reforms could
lead to the destabilization of the pharmaceutical market and thus having a nega-
tive impact on the quality of the provided services and products.
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